Caelum Biosciences Announces Data on CAEL-101 in AL Amyloidosis Selected for Oral Presentation at 59th American Society of Hematology Annual Meeting
01. November 2017 09:05 ET
|
Caelum Biosciences, Inc.
NEW YORK, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Caelum Biosciences, Inc. (“Caelum”), a Fortress Biotech, Inc. (NASDAQ:FBIO) Company focused on developing treatments for rare and life-threatening...